Logo

Takeda and Ovid Report Results of Soticlestat (TAK-935/OV935) in P-II ELEKTRA Study for Dravet Syndrome or Lennox-Gastaut Syndrome

Share this

Takeda and Ovid Report Results of Soticlestat (TAK-935/OV935) in P-II ELEKTRA Study for Dravet Syndrome or Lennox-Gastaut Syndrome

Shots:

  • The P-II ELEKTRA study involves assessing of soticlestat vs PBO in pediatric patients- aged 2-17 yrs.- with highly refractory epileptic seizures associated with DS (convulsive seizures) or LGS (drop seizures)
  • Results: meeting its 1EPs i.e. reduction in DS & LGS (27.8% vs 3.1% & 29.8% vs 0.0%) during the 12-wks. maintenance period & 20-wks. treatment period (titration plus maintenance) respectively. In DS cohort- reduction in convulsive seizure (33.8% vs 7.0%) during the full 20-week treatment period- following which companies are planning to initiate P-III program
  • In the LGS cohort- reduction in drop seizure frequency (20.6% vs 6.0%) during the full 20-week treatment period of the study. Soticlestat is a potent- highly selective- oral- first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H)

­ Ref: PRNewswire | Image: Takeda

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions